1999Journal of Huaihai MedicineRequires access

Clinical observation of uterine leiomyoma treated with small dose of mifepristone

Xu Wei

Open publisher page 0 citations

Abstract

Objective To observe the result of uterine leiomyoma treated with small dose of mifepristone. Methods Twenty - five patients with uterine leiomyoma , who was diagnosed by vagninal examination and ultra-sonography were treated with 12.5 mg of mifepriston daily and lasted for 3 monthes , 5 of them lasted for 6 mon-thes. Results After taking mifepristone for 3 monthes, the volume of leiomyoma reduced 63. 8% (P0. 01)and after taking mifepristone for 6 monthes, the volume of leiomyoma reduced 65. 2%. There was no significant difference between the two treated groups (P0. 05). During treatment amenorrhea occurred and after treatment the symptoms of dysmenorrhea, hypermenorrhea, irregular uterine bleeding were improved obviously in all patients. Conclution Takeing small dose of mifepristone daily is considered to be a more ideal methods to treat u-terine leiomyoma in young patients with symptomatic leiomyoma (uterine sizethat of 12 weeks of gestation) and perimenopausal patients. The best course of treatment is 3 monthes.

About this research paper

What this paper is about

Objective To observe the result of uterine leiomyoma treated with small dose of mifepristone. Methods Twenty - five patients with uterine leiomyoma , who was diagnosed by vagninal examination and ultra-sonography were treated with 12.5 mg of mifepriston daily and lasted for 3 monthes , 5 of them lasted for 6 mon-thes. Results After taking mifepristone for 3 monthes, the volume of leiomyoma reduced 63. 8% (P0. 01)and after taking mifepristone for 6 monthes, the volume of leiomyoma reduced 65. 2%. There was no significant difference between the two treated groups (P0. 05). During treatment amenorrhea occurred and after treatment the symptoms of dysmenorrhea, hypermenorrhea, irregular uterine bleeding were improved obviously in all patients. Conclution Takeing small dose of mifepristone daily is considered to be a more ideal methods to treat u-terine leiomyoma in young patients with symptomatic leiomyoma (uterine sizethat of 12 weeks of gestation) and perimenopausal patients. The best course of treatment is 3 monthes.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To observe the result of uterine leiomyoma treated with small dose of mifepristone. Methods Twenty - five patients with uterine leiomyoma , who was diagnosed by vagninal examination and ultra-sonography were treated with 12.5 mg of mifepriston daily and lasted for 3 monthes , 5 of them lasted for 6 mon-thes. Results After taking mifepristone for 3 monthes, the volume of leiomyoma reduced 63. 8% (P0. 01)and after taking mifepristone for 6 monthes, the volume of leiomyoma reduced 65. 2%. There was no significant difference between the two treated groups (P0. 05). During treatment amenorrhea occurred and after treatment the symptoms of dysmenorrhea, hypermenorrhea, irregular uterine bleeding were improved obviously in all patients. Conclution Takeing small dose of mifepristone daily is considered to be a more ideal methods to treat u-terine leiomyoma in young patients with symptomatic leiomyoma (uterine sizethat of 12 weeks of gestation) and perimenopausal patients. The best course of treatment is 3 monthes.

Key concepts: Mifepristone, Medicine, Leiomyoma, Amenorrhea, Uterine leiomyoma, Gynecology, Obstetrics, Surgery

Related papers

Back to paper searchBrowse research topicsOriginal source
Clinical observation of uterine leiomyoma treated with small dose of mifepristone — Research Paper | ScholarLens